Neurocrine Biosciences market cap NBIX

Share price times shares outstanding: what the whole company sells for, since 2011.

Neurocrine Biosciences is worth $14.5B at the close on Oct 23, 2026, at $142.70 a share.

That is up 2% over the last year and up 45% over five years.

Its highest close in our data was $17.8B in Jul 2026.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$14.5B	$12.5B	$17.8B	+0%
2025	$14.5B	$9.1B	$15.5B	+3%
2024	$14.1B	$11.5B	$15.5B	+9%
2023	$12.9B	$8.9B	$12.9B	+13%
2022	$11.5B	$7.1B	$12.2B	+42%
2021	$8.1B	$7.6B	$10.9B	−10%
2020	$9B	$7.4B	$12.1B	−10%
2019	$10B	$6.8B	$10.8B	+61%
2018	$6.2B	$6.2B	$11.1B	−10%
2017	$6.9B	$3.5B	$6.9B	+104%
2016	$3.4B	$3B	$4.7B	−31%
2015	$4.9B	$1.7B	$5B	+182%
2014	$1.7B	$649.9M	$1.9B	+175%
2013	$628.3M	$555.6M	$1.1B	+28%
2012	$492.6M	$431M	$596.8M	+5%
2011	$469.7M	$303.8M	$469.7M	n/a

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

Company	Market cap
NBIXNeurocrine Biosciences	$14.5B
HALOHalozyme Therapeutics	$14.3B
EXELExelixis	$16B
TECHBIO-TECHNE	$11.4B
RGENRepligen	$10B
KRYSKrystal Biotech	$9.2B
INCYIncyte	$23.5B
UTHRUnited Therapeutics	$25.2B
ALNYAlnylam Pharmaceuticals	$30B
ONCBeOne Medicines	$42.9B
REGNRegeneron Pharmaceuticals	$82.9B
Peer median	$19.7B